NYSEMKT: YCBDCbdmd Inc Stock
$0.23+0.01 (+4.55%)
Updated Apr 17, 2025
YCBD Price
$0.23
Fair Value Price
N/A
Market Cap
$1.44M
52 Week Low
$0.18
52 Week High
$1.25
P/E
-0.14x
P/B
0.81x
P/S
0.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$19.22M
Earnings
-$2.69M
Gross Margin
61.6%
Operating Margin
-13.9%
Profit Margin
-34.8%
Debt to Equity
5.48
Operating Cash Flow
-$565k
Beta
1.04
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
YCBD Overview
cbdMD, Inc. produces and distributes various cannibidiol (CBD) products. It owns and operates the consumer hemp-based CBD brand, cbdMD. The company's product categories include CBD tinctures, capsules, gummies, bath bombs, topical creams, and animal treats and oils. It also offers pet related CBD products under the Paw CBD brand name. The company distributes its products through an e-commerce Website, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was founded in 2015 and is headquartered in Charlotte, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine YCBD's potential to beat the market
- YCBD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
YCBD
RankedUnranked of 54
RankedUnranked of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important YCBD news, forecast changes, insider trades & much more!
YCBD News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how YCBD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
YCBD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
YCBD is good value based on its book value relative to its share price (0.81x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.99x)
P/B vs Industry Valuation
YCBD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more YCBD due diligence checks available for Premium users.
Valuation
YCBD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
20.48x
Market
27.98x
YCBD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.81x
Industry
1.99x
YCBD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
YCBD's financial health
Profit margin
Revenue
$5.1M
Net Income
$15.1k
Profit Margin
-19.3%
YCBD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
YCBD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.5M
Liabilities
$9.8M
Debt to equity
5.48
YCBD's short-term liabilities ($9.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YCBD's short-term assets ($6.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YCBD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
YCBD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$317.9k
Investing
-$164.4k
Financing
$0.0
YCBD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
YCBD vs Pharmaceutical Stocks
Cbdmd Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.